Differential cardiac impacts of hematological malignancies and solid tumors: a histopathological and biomarker study

Table 9 Cancer therapy comparison: hematological malignancies (HMs) vs solid tumors (STs)

	HM (n = 144)	ST (n=50)	p Value
Cancer Therapy
Alkylating agents	84 (58%)	30 (60%)	0.8
Cytotoxic agents	111 (77%)	1 (2.0%)	< 0.001
Antimetabolites	70 (49%)	22 (44%)	0.6
Anthracyclines and topoisomerase inhibitors	79 (55%)	19 (38%)	0.040
Targeted therapy	31 (22%)	15 (30%)	0.2
Anti-mitotic agents	24 (17%)	19 (38%)	0.002
Other therapies	56 (39%)	9 (18%)	0.007
Radiotherapy (n=198, 164)	59 (30%)	77 (47%)	< 0.001

Alkylating agents: Bendamustine, Busulfan, CARBOplatin, CISplatin, Cyclophosphamide, Dacarbazine, Ifosfamide, Melphalan, Mesna, OXALIplatin, Procarbazine, Temozolomide, Thiotepa, Trabectedin
Cytotoxic agents: Arsenic Trioxide, Bleomycin, Carmustine, Clofarabine, Cytarabine, Decitabine, Fludarabine, IDArubicin, Tretinoin
Antimetabolites: Azacitidine, Cladribine, Fluorouracil, Gemcitabine, Mercaptopurine, Methotrexate, PEMEtrexed, Pentostatin, Thioguanine
Anthracyclines and topoisomerase inhibitors: DAUNOrubicin, DOXOrubicin, Etoposide, Irinotecan, MitoXANTRONE, Topotecan
Targeted therapy: Alemtuzumab, Axitinib, Bevacizumab, Blinatumomab, Brentuximab Vedotin, Cetuximab, Dabrafenib, Dasatinib, Gemtuzumab Ozogamicin, Ibrutinib, Imatinib Mesylate, Necitumumab, Nilotinib, Nivolumab, Pembrolizumab, Pertuzumab, Polatuzumab Vedotin, Ramucirumab, RiTUXimab, Ruxolitinib, Sorafenib, Trastuzumab
Anti-mitotic agents: DOCEtaxel, PACLitaxel, VinBLAStine, vinCRIStine, VinORELbine
Other therapies: Aldesleukin, Asparaginase, Bortezomib, Carfilzomib, Denileukin Diftitox, EriBULin Mesylate, Fulvestrant, Goserelin Acetate, Hydroxyurea, Lenalidomide, Letrozole, Leuprolide, Megestrol Acetate, Pegaspargase, Porfimer, Tamoxifen, Thalidomide, Venetoclax, Zosuquidar

ISSN: 2057-3804